Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Weighing In On DPP-IV Inhibitors: Galvus, Januvia Both Highlight Weight Profiles

This article was originally published in The Pink Sheet Daily

Executive Summary

Data presented on the competing dipeptidyl peptidase IV inhibitors from Novartis and Merck at the American Diabetes Association similarly tout weight loss and other side effect advantages versus standard type 2 diabetes drugs.

You may also be interested in...



Merck Submits Januvia/Metformin NDA Aiming To Launch First Fixed-Dose DPP-4 Inhibitor

Novartis, meanwhile, is positioning its investigational DPP-4 inhibitor Galvus as an add-on to metformin.

Merck Submits Januvia/Metformin NDA Aiming To Launch First Fixed-Dose DPP-4 Inhibitor

Novartis, meanwhile, is positioning its investigational DPP-4 inhibitor Galvus as an add-on to metformin.

Januvia Dose Adjustment For Renal Insufficiencies Not Needed For Galvus

Merck's type 2 diabetes treatment Januvia may necessitate dose adjustment for patients with renal insufficiencies; a precaution not necessary for Novartis' competing dipeptidyl peptidase IV inhibitor Galvus, the Swiss firm maintained

Topics

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel